<DOC>
	<DOCNO>NCT01530490</DOCNO>
	<brief_summary>The purpose study ass whether , GnRH agonist vitro fertilization ( IVF ) cycle , risk ovarian hyperstimulation syndrome ( OHSS ) , addition cabergoline hydroxyethyl starch infusion could decrease OHSS incidence severity .</brief_summary>
	<brief_title>Cabergoline Hydroxyethyl Starch Ovarian Hyperstimulation Syndrome Prevention</brief_title>
	<detailed_description>Women undergo IVF cycle GnRH agonist protocol , risk OHSS ( 20 follicle observe large 12 mm diameter and/or estradiol level 3000-5000 pg/mL ) . Slow infusion 500 ml 6 % HES follicular aspiration alone combine 0.5 mg cabergoline administration 8 day , start day hCG administration .</detailed_description>
	<mesh_term>Ovarian Hyperstimulation Syndrome</mesh_term>
	<mesh_term>Ovarian Diseases</mesh_term>
	<mesh_term>Cabergoline</mesh_term>
	<mesh_term>Hydroxyethyl Starch Derivatives</mesh_term>
	<criteria>risk OHSS invite participate study age &gt; 40 year</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>IVF</keyword>
	<keyword>ovarian hyperstimulation syndrome</keyword>
	<keyword>cabergoline</keyword>
	<keyword>hydroxyethyl starch</keyword>
	<keyword>prevention</keyword>
</DOC>